Universe Pharmaceuticals INC
UPCUniverse Pharmaceuticals INC in brief
Universe Pharmaceuticals INC is a listed company in the Biotechnology industry, based in China. It was founded in 2019. Its market value was $28 M on 1 August 2026, which makes it the 23,240th largest listed company in the world and the 4,206th largest in China on this site. In the year to September 2025 it had sales of $17.9 B and a net loss of $3.7 B. It employs about 69 people and Gang Lai is its chief executive. Its largest product and service lines by sales in 2025 were Revenue from sales of self-manufactured TCMD products (74%) and Revenue from sales of third-party products (26%). Its shares trade under the symbol UPC (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Universe Pharmaceuticals INC
As we introduce new products to our customers, we may be required to comply with additional laws and regulations that are yet to be determined. To comply with such additional laws and regulations, we may be required to obtain necessary certificates, licenses or permits, as well as expend additional resources to monitor regulatory and policy developments. Our failure to adequately comply with such additional laws and regulations may delay, or possibly prevent, some of our products from being offered to customers, which may have a material adverse effect on our business, financial condition and results of operations.
From the company's annual report filed with the US SEC: read the report
Universe Pharmaceuticals INC timeline
- 2019
- 🏁· approximateFounded
- 2020
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2021
- 💰Record net income of $11 millionFY2021, the highest profit of the 3 years on record.
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 24 March 2021; shares registered for exchange trading on 17 March 2021.
- 2023
- 💰Revenue passed $1 billionFY2023 revenue of $32.3 billion, up from $40 million in FY2022.
- 💰Revenue passed $10 billionFY2023 revenue of $32.3 billion, up from $40 million in FY2022.
- 💰Record revenue of $32.3 billionFY2023, the highest of the 7 years on record.
Events of Universe Pharmaceuticals INC from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in China: #4,973 (Jan 2022) · #5,156 (Dec 2022) · #5,172 (Jul 2023) · #5,450 (Jan 2024) · #4,502 (Mar 2026) · #4,227 (Aug 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 0.0×
- Price / book
- 0.0×
- Free cash flow yield
- -18996.8%
- Net margin (TTM)
- -20.6%
- Operating margin
- -16.3%
- Return on equity
- -6.5%
- Liabilities / assets
- 19.0%
- Revenue growth
- -22.4%
- R&D / revenue
- 3.8%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Sep 2025 | $17.9B | -22.4% | $-2.9B | $-3.7B | -20.6% |
| Sep 2024 | $23.0B | -28.7% | $-8.0B | $-8.7B | -37.9% |
| Sep 2023 | $32.3B | +80390.1% | $-4.0B | $-6.6B | -20.4% |
| Sep 2022 | $40M | -16.3% | $-7M | $-8M | -19.7% |
| Sep 2021 | $48M | +56.3% | $14M | $11M | 23.6% |
| Sep 2020 | $31M | -7.6% | $10M | $8M | 24.6% |
| Sep 2019 | $33M | — | $10M | $8M | 22.7% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Sep 2025 | $-5.1B | $267M | $-5.3B | $-8.06 | — |
| Sep 2024 | $-9.5B | $208M | $-9.7B | $-626.96 | — |
| Sep 2023 | $1.1B | $44M | $1.1B | $-1089.21 | — |
| Sep 2022 | $-1M | $0M | $-1M | $-1309.11 | — |
| Sep 2021 | $-2M | $0M | $-3M | $3.58 | — |
| Sep 2020 | $6M | $0M | $6M | $0.47 | — |
| Sep 2019 | $13M | $0M | $13M | $0.47 | — |
SEC filings
- Oct 6, 20266-KReport of foreign issuer
- Sep 1, 20266-KReport of foreign issuer
- Jul 31, 20266-KReport of foreign issuer
- Jul 29, 20266-KReport of foreign issuer
- Jun 26, 20266-KReport of foreign issuer
- May 14, 20266-KReport of foreign issuer
- Apr 16, 20266-KReport of foreign issuer
- Feb 11, 20266-KReport of foreign issuer
- Jan 29, 202620-FAnnual report (foreign issuer) · period to Sep 2025
- Sep 3, 20256-KReport of foreign issuer
- Aug 26, 20256-KReport of foreign issuer
- Jul 29, 20256-KReport of foreign issuer
Official filings of Universe Pharmaceuticals INC with the US Securities and Exchange Commission.
Annual results
- Revenue
- $17.9 B
- Operating income
- $-2.9 B
- Net income
- $-3.7 B
For year ending September-2025 · source: SEC filing
Balance sheet
- Total assets
- $69.3 B
- Total liabilities
- $13.2 B
- Total equity
- $56.1 B
As of September-2025
Top 7 institutional investors in Universe Pharmaceuticals INC#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Geode Capital Management, LLC | 44,531 | New | 0.50% | $0 M | Nov 6, 2026 |
| 2 | Citadel Advisors LLC | 14,625 | New | 0.17% | $0 M | Nov 16, 2026 |
| 3 | Jane Street Group, LLC | 11,292 | New | 0.13% | $0 M | Nov 12, 2026 |
| 4 | Osaic Holdings, Inc. | 6,172 | 0 (0.00%) | 0.07% | $0 M | Nov 12, 2026 |
| 5 | UBS Group AG | 1,550 | -12,817 (-89.21%) | 0.02% | $0 M | Nov 10, 2026 |
| 6 | National Bank Of Canada /fi/ | 1 | New | 0.00% | $0 M | Nov 16, 2026 |
| 7 | Caitong International Asset Management Co., Ltd | 1 | -11 (-91.67%) | 0.00% | $0 M | Oct 29, 2026 |
Insider trading at Universe Pharmaceuticals INC#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Gang LaiChief Executive Officer, Director, 10% owner | Grant or award | +71,890 | — | —local | 71,890 | Form 4 |
| filed | Gang LaiChief Executive Officer, Director, 10% owner | Grant or award | +12,610 | — | —local | 12,610 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals. This company files with the SEC as a foreign issuer; its insiders often report prices in the home currency, so amounts are as filed and not converted to dollars
Markets and events: Universe Pharmaceuticals INC#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2026-09-02 13:34 UTC, code LUDP, resumed 13:39 UTC
- 2026-06-29 13:31 UTC, code LUDP, resumed 13:36 UTC
- 2026-04-23 13:30 UTC, code LUDP, resumed 13:40 UTC
- 2025-12-26 17:37 UTC, code LUDP, resumed 17:42 UTC
- 2025-12-26 16:03 UTC, code LUDP, resumed 16:08 UTC
Fails to deliver
- : 1,352 shares at $1.93
- : 866 shares at $2.24
- : 2,419 shares at $4.30
- : 1,412 shares at $3.98
- : 1,598 shares at $4.27
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Universe Pharmaceuticals INC scorecard#
Passes 3 of the 13 checks that could be worked out: strongest in profitability (2 of 5), weakest in growth (0 of 4). Fiscal year 2025; market cap of Aug 1, 2026.
Valuationnot known
- –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
- –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
- –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
Growth0 of 4
- ✗Revenue grew in the newest year-22.4%Revenue down 22.4% in fiscal 2025.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-8.06 vs -626.96Diluted EPS -8.06 in fiscal 2025 against -626.96 the year before (report's currency).
- ✗Net income higher than five years earlier-$3.7 B-$3.7 B in fiscal 2025 against $8 M in 2020.
- ✗Revenue rose in at least four of the last five years2 of 5Revenue rose in 2 of the five years to fiscal 2025.
Profitability2 of 5
- ✗Profitable in the newest year-$3.7 BNet income -$3.7 B in fiscal 2025.
- ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
- ✓Operating margin above its peers' median-16.3%-16.3% against Biotechnology's median of -60.5% (243 companies).
- ✗Return on equity above 15%-7.2%-7.2% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-16.3%-16.3% in fiscal 2025 against -17.5% in 2022.
Financial health1 of 4
- ✓Short-term assets cover short-term liabilities4.1×Current ratio 4.07 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- ✗Operating income covers interest five times-10.1×Operating income -10.1 times interest in fiscal 2025.
- ✗Cash from operations positive in each of the last three years1 of 3Positive in 1 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone0.54Z-score 0.54 (distress zone) for fiscal 2025.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Universe Pharmaceuticals INC's statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -16.3% | -60.5% | |
| Net margin | -20.6% | -68.9% | |
| Return on equity | -7.2% | -61.0% | |
| Revenue growth | -22.4% | 15.8% | |
| Free cash flow margin | -29.8% | -61.5% |
3of 8on the Piotroski tests of financial strength
- Revenue fell 22.4% against the year before.
- Net loss of $3.7 billion, the 4th loss-making year in a row.
- Free cash flow was negative: -$5.3 billion.
- Operating income covers the interest bill only -10.1 times.
Universe Pharmaceuticals INC: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Sep 30, 2025 | FY 2024to Sep 30, 2024 | FY 2023to Sep 30, 2023 | FY 2022to Sep 30, 2022 | FY 2021to Sep 30, 2021 | FY 2020to Sep 30, 2020 | FY 2019to Sep 30, 2019 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 17,859−22.4%100% | 23,024r23−28.7%100% | 32,309r32+80384%100% | 40−16.3%100% | 48+56.3%100% | 31−7.6%100% | 33—100% | |
| Cost of revenue | 11,558−31.8%64.7% | 16,953r17−22.9%73.6% | 21,994r22+120401%68.1% | 18−19.4%45.5% | 23+36.4%47.2% | 17−16.2%54.1% | 20—59.7% | |
| Gross profit | 6,301+3.8%35.3% | 6,072r6.1−41.1%26.4% | 10,315r10+47020%31.9% | 22−13.6%54.5% | 25+79.7%52.8% | 14+5.1%45.9% | 13—40.3% | |
| Research and development | 672−77.8%3.8% | 3,031r3.0−37.6%13.2% | 4,859r4.9+63457%15.0% | 7.6+39.9%19.0% | 5.5+837%11.4% | 0.6−5.7%1.9% | 0.6—1.9% | |
| Selling and marketing | 4,798−41.3%26.9% | 8,171r8.2+20.5%35.5% | 6,784r6.8+35448%21.0% | 19+542%47.5% | 3.0+91.2%6.2% | 1.6−1.5%5.1% | 1.6—4.8% | |
| General and administrative | 3,748+29.7%21.0% | 2,890r2.9+9.5%12.6% | 2,639r2.2+120773%8.2% | 2.2r2.6−33.8%5.4% | 3.3+93.5%6.9% | 1.7+16.9%5.5% | 1.5—4.4% | |
| Operating expenses | 9,217−34.6%51.6% | 14,092r14−1.3%61.2% | 14,281r14+49298%44.2% | 29r29+146%72.0% | 12+205%24.5% | 3.8+5.1%12.5% | 3.7—11.0% | |
| Operating income | −2,916—−16.3% | −8,020r−8.0—−34.8% | −3,966r−3.5—−12.3% | −7.0r−7.4−152%−17.5% | 14+32.6%28.3% | 10+5.1%33.4% | 9.8—29.4% | |
| Interest expense and finance costs | 289−5.0%1.6% | 305r0.3+60.1%1.3% | 190r0.2+117008%0.6% | 0.2+59.8%0.4% | 0.1−17.9%0.2% | 0.1−4.3%0.4% | 0.1—0.4% | |
| Share of profit of associates | 65+104%0.4% | 32r0.0+2.8%0.1% | 31r0.0+80422%0.1% | 0.0+25.2%0.1% | 0.0+41.3%0.1% | 0.0−18.4%0.1% | 0.0—0.1% | |
| Other non-operating income (expense) | −756—−4.2% | −101r−0.1—−0.4% | −361r−0.3—−1.1% | −0.1r−0.5−185%−0.2% | 0.1—0.2% | −0.2—−0.5% | −0.1—−0.3% | |
| Income before tax | −3,672—−20.6% | −8,121r−8.1—−35.3% | −4,327r−3.8—−13.4% | −7.1r−8.0−152%−17.7% | 14+35.4%28.5% | 10+4.6%32.9% | 9.7—29.0% | |
| Income tax | — | 607r0.6−73.1%2.6% | 2,254r2.3+276305%7.0% | 0.8r0.8−65.4%2.0% | 2.4−7.2%4.9% | 2.5+21.0%8.3% | 2.1—6.3% | |
| Net income including minority interests | — | — | — | −8.7−177%−21.8% | 11+49.8%23.6% | 7.6+0.1%24.6% | 7.6—22.7% | |
| Net income attributable to shareholders | −3,672—−20.6% | −8,727r−8.7—−37.9% | −6,581r−6.2—−20.4% | −7.9r−8.7−170%−19.7% | 11+49.8%23.6% | 7.6—24.6% | — | |
| Earnings per share, basic | -8.06—— | -626.96—— | -1,089.21r-1.70—— | -1,309.11r-0.40−36667%— | 3.58r0.60+662%— | 0.470.0%— | 0.47—— | |
| Earnings per share, diluted | -8.06—— | -626.96—— | -1,089.21r-1.70—— | -1,309.11r-0.40−36667%— | 3.58r0.60+662%— | 0.470.0%— | 0.47—— | |
| Shares, weighted average (basic) | 0.5+3175%— | 0.0+130%— | 0.0r3.60.0%— | 0.0r22−99.8%— | 3.2r19−80.2%— | 16—— | — | |
| Shares, weighted average (diluted) | 0.5+3175%— | 0.0+130%— | 0.0r3.60.0%— | 0.0r22−99.8%— | 3.2r19−80.2%— | 160.0%— | 16—— | |
| Balance sheet | ||||||||
| Cash and cash equivalents | 33,592+13.9%48.5% | 29,498r29+558014%43.4% | 5.3−7.5%12.7% | 5.7−29.3%9.6% | 8.1−19.7%11.5% | 10+217%34.9% | 3.2—— | |
| Short-term investments | — | — | 13+0.5%31.7% | 13−4.2%22.1% | 14—19.6% | — | — | |
| Receivables | 13,008+0.8%18.8% | 12,906r13+117067%19.0% | 11r11−27.5%26.4% | 15−2.5%25.5% | 16+43.2%22.2% | 11—37.7% | — | |
| Inventory | 2,193+26.3%3.2% | 1,737r1.7+51857%2.6% | 3.3+51.5%8.0% | 2.2−10.4%3.7% | 2.5+29.2%3.5% | 1.9—6.6% | — | |
| Other current assets | 40−95.3%0.1% | 852r0.9+2292700%1.3% | 0.0r0.6−97.8%0.1% | 1.7—2.9% | — | — | — | |
| Current assets | 53,604+3.8%77.3% | 51,638r52+204247%76.0% | 25r37−39.1%60.6% | 42−17.8%69.7% | 50+117%72.0% | 23—80.8% | — | |
| Property, plant and equipment | 3,584+0.4%5.2% | 3,568r3.6+96335%5.3% | 3.7−13.0%8.9% | 4.3−9.2%7.1% | 4.7+5.7%6.7% | 4.4—15.4% | — | |
| Other intangible assets | 297+12.9%0.4% | 263r0.3+176822%0.4% | 0.1−5.6%0.4% | 0.2+6.0%0.3% | 0.1r0.2−15.0%0.2% | 0.2—0.6% | — | |
| Investments in associates | 702−1.4%1.0% | 712r0.7+1.4%1.0% | 702r0.7+99823%1683% | 0.7—1.2% | — | — | — | |
| Non-current assets | 15,700−3.8%22.7% | 16,316r16+99054%24.0% | 16r16−8.8%39.4% | 18−8.3%30.3% | 20+256%28.0% | 5.5—19.2% | — | |
| Total assets | 69,303+2.0%100% | 67,953r68+162762%100% | 42r53−29.9%100% | 60−15.1%100% | 70+144%100% | 29—100% | — | |
| Accounts payable | 1,670−66.0%2.4% | 4,915r4.9+107086%7.2% | 4.6r4.6+49.1%11.0% | 3.1−42.1%5.2% | 5.3+97.3%7.6% | 2.7—9.3% | — | |
| Debt due within a year | 2,107—3.0% | — | — | — | — | — | — | |
| Current liabilities | 13,174−35.1%19.0% | 20,313r20+147584%29.9% | 14r14+5.0%33.0% | 13+16.8%22.0% | 11+40.1%16.0% | 8.0—27.8% | — | |
| Non-current liabilities | — | 2,137—3.1% | — | — | — | — | — | |
| Total liabilities | 13,174−41.3%19.0% | 22,450r22+163125%33.0% | 14—33.0% | — | — | — | — | |
| Retained earnings | −13,844—−20.0% | −10,172r−10—−15.0% | −1.4r10−109%−3.5% | 16−34.9%27.4% | 25+82.4%35.7% | 14—47.7% | — | |
| Shareholders' equity | 56,130+23.4%81.0% | 45,503r46+62.7%67.0% | 27,970r40−20.8%67035% | 35,331r46+75084%59339% | 47r59+126%67.0% | 21+68.0%72.2% | 12—— | |
| Total liabilities and equity | 69,303+2.0%100% | 67,953r68+162762%100% | 42r53−29.9%100% | 60−15.1%100% | 70+144%100% | 29—100% | — | |
| Shares outstanding | 0.6+1214%— | 0.0+607%— | 0.0r3.6−99.8%— | 3.6r22−83.3%— | 22+35.9%— | 16—— | — | |
| Cash-flow statement | ||||||||
| Depreciation and amortization | 517+6.5%2.9% | 486r0.5−4.5%2.1% | 509r0.5+95187%1.6% | 0.5+19.5%1.3% | 0.4+9.0%0.9% | 0.4−2.0%1.3% | 0.4—1.3% | |
| Cash from operating activities | −5,052—−28.3% | −9,507r−9.5−951%−41.3% | 1,117r1.1—3.5% | −1.3r−1.3—−3.2% | −2.1−134%−4.3% | 6.1−53.7%19.9% | 13—39.7% | |
| Capital expenditure | −267—−1.5% | −208r−0.2—−0.9% | −44r−0.0—−0.1% | −0.1—−0.2% | −0.4—−0.9% | −0.1—−0.2% | −0.1—−0.3% | |
| Intangible assets bought | −80—−0.5% | −117r−0.1—−0.5% | — | — | — | — | — | |
| Cash from investing activities | −342—−1.9% | −361r−0.4—−1.6% | −44r−0.0—−0.1% | −3.9—−9.7% | −27—−56.4% | −0.1—−0.2% | −0.1—−0.3% | |
| Shares issued | 15,000−40.0%84.0% | 25,000r25—109% | — | — | — | — | — | |
| Dividends paid | — | — | — | — | — | — | −16—−48.2% | |
| Cash from financing activities | 9,726−71.4%54.5% | 33,954r34—147% | −1,391r−1.4−42013%−4.3% | 3.3−87.5%8.3% | 27+5554%55.4% | 0.5—1.5% | −16—−48.2% | |
| Exchange-rate effect on cash | −238−288%−1.3% | 126r0.1—0.5% | −108r−0.1—−0.3% | −0.5r−0.5−186%−1.2% | 0.6+59.4%1.2% | 0.3—1.1% | −0.1—−0.4% | |
| Change in cash | 4,094−83.1%22.9% | 24,212r24—105% | −426r−0.4—−1.3% | −2.4—−5.9% | −2.0−129%−4.1% | 6.9—22.4% | −3.0—−9.1% | |
| Report | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2025. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Universe Pharmaceuticals INC sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Revenue from sales of self-manufactured TCMD products$13.3 B74%-5.5%
- Revenue from sales of third-party products$4.6 B26%-49%
Source: SEC annual report (XBRL data) · as of Sep 30, 2025
Where Universe Pharmaceuticals INC operates: 1 country#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue.
Only the headquarters country is on file for Universe Pharmaceuticals INC: no subsidiaries, branches, offices or country revenue elsewhere in the GLEIF register, its SEC filings or Wikidata.
| Country | Presence | Revenue there |
|---|---|---|
| 🇨🇳 China | Headquarters1 office | — |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file; map outlines from Natural Earth. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
How Universe Pharmaceuticals INC compares in Biotechnology
- Market cap$28 M · higher than 20% of 726
- Revenue$17.9 B · highest of 647
- Net margin-20.6% · higher than 60% of 408
- Revenue growth-22.4% · higher than 29% of 438
- Price / sales0.0× · lowest of 339
- Price / book0.0× · lowest of 534
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Universe Pharmaceuticals INC🇨🇳 | $28 M | — | -20.6% | -22.4% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Aug 1, 2026
- Annual results:
- For year ending September-2025
- Balance sheet:
- As of September-2025
- Employees:
- As of September 30, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Universe Pharmaceuticals INC? Verify and update this profile — free
Show Universe Pharmaceuticals INC's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.